Company Directory

Microbiome modulator ingredients for metabolic health and disease prevention

OptiBiotix Health is a biotechnology company developing and licensing microbiome modulator products for use in food ingredients, dietary supplements, and nutraceuticals. Its portfolio includes patented prebiotic and probiotic formulations targeting weight management, cholesterol reduction, cardiovascular health, and gut microbiome diversity. Products are licensed to food and supplement manufacturers globally. The company operates through subsidiaries including OptiBiotix Ltd and holds a majority stake in SkinBioTherapeutics plc and ProBiotix Health Ltd.

Gene therapy company targeting complement-mediated ocular diseases

Complement Therapeutics is a clinical-stage biotechnology company developing gene therapies and protein-based therapeutics for diseases driven by dysregulation of the complement immune pathway. A spin-out from the University of Manchester, the company's lead programme CTx001 is an AAV-based gene therapy for geographic atrophy, an advanced form of dry age-related macular degeneration. The company is also developing the Complement Precision Medicine platform for quantification of complement cascade proteins to support diagnosis and patient stratification.

C. elegans whole-organism platform for preclinical drug and compound screening

Magnitude Biosciences Limited is a contract research organisation providing preclinical drug discovery and compound screening services using Caenorhabditis elegans as a whole-organism model. Its proprietary biophotonics platform enables automated, high-throughput, non-invasive monitoring of health and lifespan metrics across large worm populations, supporting compound library screening, pathway analysis, microbiome assessment, and toxicology studies. The platform accelerates early compound triage for pharmaceutical, biotechnology, and nutrition clients, reducing reliance on mammalian models.

Single-workflow sequencing technology capturing genetic and epigenetic data

biomodal is a Cambridge-based life sciences technology company developing multiomics sequencing solutions that simultaneously capture genetic and epigenetic information from a single DNA sample. Its multiomics platform detects the canonical four DNA bases alongside 5-methylcytosine and 5-hydroxymethylcytosine modifications at single-base resolution, without requiring additional hardware or bisulfite treatment. The technology is compatible with existing sequencing infrastructure and targets applications in oncology, neurodegenerative disease research, and liquid biopsy diagnostics.

Topical peptide therapeutics targeting inflammatory skin disease

Carocell Bio is a pre-clinical stage biotechnology company developing proprietary peptide-based therapeutics for inflammatory diseases. Its pipeline centres on topical formulations that inhibit mitogen-activated protein kinase (MAPK/p38), a key regulator of the inflammatory cascade. Lead programmes target atopic dermatitis, inflammatory bowel disease, burns and scarring. Candidates are formulated using nanoparticle delivery systems to enhance skin penetration, and have demonstrated activity in human biopsy studies.

Non-invasive skin epigenomics platform for clinical and cosmetic research

Mitra Bio is a contract research organisation providing a non-invasive skin epigenomics platform to pharmaceutical and cosmetic companies conducting clinical trials on dermatological and age-reversal interventions. Using tape-strip skin sampling combined with whole-genome DNA methylation sequencing and bioinformatic analysis, the company generates biological age assessments and predictive biomarkers to evaluate treatment efficacy and guide compound development. Mitra Bio also collaborates with clinical partners on epigenetic approaches to melanoma screening.

RNA therapeutics targeting cellular senescence and age-related disease

Senisca is a preclinical-stage biotechnology company developing oligonucleotide and small molecule therapeutics that reverse cellular senescence by restoring RNA splicing factor activity. Its platform targets the molecular mechanisms of cellular ageing and has broad applicability across multiple age-related diseases. Lead indications include idiopathic pulmonary fibrosis, osteoarthritis, and age-related macular degeneration. The company also pursues a cosmeceutical programme targeting aesthetic signs of skin ageing.

AI-driven drug discovery targeting necrosis and age-related disease

LinkGevity is a preclinical-stage biotechnology company developing anti-necrotic therapeutics for age-related and degenerative diseases. Founded in 2023 and based at Babraham Research Campus, the company's proprietary Blueprint Theory of Ageing identifies necrosis as a key driver of biological decline, informing its AI-enabled drug discovery platform. Its lead programme targets kidney disease, with broader applications across age-related conditions.

API-first diagnostic infrastructure and biomarker services for healthcare companies

Hurdle is a London-based diagnostics-as-a-service company providing end-to-end diagnostic infrastructure to telehealth companies, consumer health brands, pharmaceutical companies, and clinical research organisations. Its platform integrates sample collection kit manufacturing, accredited laboratory networks, logistics, and data management tools into a single API-connected system. The company also conducts biomarker research, with published work in DNA methylation-based epigenetic biomarkers for biological age and systemic inflammation.

Non-invasive mitochondrial DNA damage testing for skin health research

Skin Life Analytics is a biotechnology company providing PCR-based testing services that quantify mitochondrial DNA damage in skin using non-invasive swab sampling. The technology detects molecular markers of skin ageing, UV damage, and environmental stress before visible signs appear. Services include direct testing for aesthetic clinics, contract laboratory projects for cosmetic ingredient and brand R&D. The platform also measures nuclear DNA damage and oxidative stress biomarkers to support evidence generation for skincare products.

Rejuvenation biology company decoding the genomics of cellular ageing reversal

clock.health is a biotechnology company developing therapies to reverse cellular ageing and extend healthspan by decoding the biological programmes that govern cell rejuvenation. Using a proprietary model in which human induced pluripotent stem cells are artificially aged then permitted to self-rejuvenate, the company conducts genome-wide CRISPR screens to identify the genes and pathways responsible. Validated targets are progressed towards therapeutic interventions, with initial human studies focusing on topical and nutraceutical applications ahead of systemic therapies.

Synthetic plant metabolites for osteoarthritis and age-related disease

AKL Therapeutics is a privately held UK pharmaceutical company developing APPA, a patented oral investigational medicine combining two synthetic plant metabolites that act synergistically to target multiple signalling pathways in osteoarthritis. Animal studies have demonstrated pain reduction and delayed cartilage degradation. APPA has completed a Phase II trial and is preparing to enter a Phase IIb study at higher doses. Recent research has also identified senolytic and senomorphic properties, expanding its potential into age-related conditions.